The Royal Marsden NHS Foundation Trust partners with NTT DATA and CARPL.ai on cancer detection
Specialist cancer treatment centre The Royal Marsden NHS Foundation Trust has partnered with technology provider NTT DATA and AI enterprise CARPL.ai to build an AI-powered radiology analysis service.
The organizations say the new partnership will transform cancer research and ultimately improve patient outcomes, marking a milestone in the use of artificial intelligence (AI) in clinical innovation.
Funded by a three-year grant from the UK’s National Institute for Health and Care Research, the partnership will support research at The Royal Marsden and the Institute of Cancer Research, including work with other research teams.
The researchers will focus on developing and evaluating AI algorithms to improve the accuracy of cancer evaluation. The work will cover sarcoma, lung, breast, brain and prostate cancers, hoping to achieve faster response times, more accurate diagnosis and better-targeted treatments.
The team will be using an MLOps clinical imaging platform, built and operated by NTT DATA. The bespoke system uses high-performance Dell servers and the latest GPU processing capacity from the CARRL.ai platform, which helps to test and manage AI algorithms.
“AI has immense potential to support clinicians in diagnosing and treating cancer earlier and more precisely,” explains Professor Dow-Mu Koh, Professor in Functional Cancer Imaging and Consultant Radiologist in Functional Imaging at The Royal Marsden. “By working with NTT DATA and CARPL.ai, we’ve created a scalable research environment that allows us to explore the full potential of AI safely and in a way that could one day transform cancer diagnosis and treatment across the NHS.”
Tom Winstanley, Chief Technology Officer at NTT DATA UK & Ireland, adds: “This service is a great example of responsible innovation in practice, showing the ethical, secure use of AI in healthcare. We are very proud to support The Royal Marsden in pushing the boundaries of cancer research.”
In Janauary, AI-driven drug discovery company Evariste announced a partnership with the University of Southampton to create one of the largest transcriptomic datasets for esophageal adenocarcinoma, a challenging and aggressive form of cancer.
